James Huang's appointment to Connect Biopharma's Board of Directors is viewed positively, with his vast biotech and investment experience anticipated to offer unique insights and aid the company's pipeline progression.
$康乃德生物(CNTB.US)$ To report possible manipulation in a stock to the U.S. Securities and Exchange Commission (SEC), you can follow these steps: 1. Visit the SEC's official website atwww.sec.gov. 2. Look for the "File a Complaint" or "Report Misconduct" section on the SEC's website. This section may be located under the "Enforcement" or "Investor Information" tab. 3. Follow the instructions provided to file a c...
$康乃德生物(CNTB.US)$Connect Biopharma Announces Rademikibart Global Phase 2b Topline Results in Adult Patients With Moderate-to-Severe Persistent Asthma announced today positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma Benzinga· 1 min ago
$康乃德生物(CNTB.US)$insiders going to pump this stock for the next three days since there is a big new coming out .. lots of groups already recommended buy signal also look at the indicators strong bullish signals
$康乃德生物(CNTB.US)$Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023
Despite Connect Biopharma Holdings' promising cash runway and reduced cash burn, the company's high expenditure relative to its market value makes its cash burn situation appear risky.
康乃德生物股票討論區
Price target for this stock is 7$ its undervalued .. sooner it will jump to 2.5 to 3$
Real peachy😁🖕🏼
If you want to report any suspected illegal practices to the SEC here ya go…
To report possible manipulation in a stock to the U.S. Securities and Exchange Commission (SEC), you can follow these steps: 1. Visit the SEC's official website at www.sec.gov. 2. Look for the "File a Complaint" or "Report Misconduct" section on the SEC's website. This section may be located under the "Enforcement" or "Investor Information" tab. 3. Follow the instructions provided to file a c...
News 📰
Update
announced today positive topline results from the global Phase 2b trial evaluating rademikibart efficacy and safety in adult patients with moderate-to-severe persistent asthma
Benzinga· 1 min ago
also look at the indicators strong bullish signals
Update
暫無評論